Regulus Therapeutics Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Regulus Therapeutics Inc in the first quarter 2025?
Regulus Therapeutics Inc recorded a cumulative net loss of $-48 million during 12 months ending in the first quarter 2025, resulting in a negative return on equity (ROE) of -57.53%.

Within the Major Pharmaceutical Preparations industry 181 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the fourth quarter 2024 from 2590 to 3104.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Mar 31 2025) I. Quarter	(Dec 31 2024) IV. Quarter	(Sep 30 2024) III. Quarter	(Jun 30 2024) II. Quarter	(Mar 31 2024) I. Quarter
Y / Y Equity Change	-35.84 %	260.64 %	207.18 %	188.79 %	-
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in Millions	-48	-46	-42	-35	-31
Return On Equity (TTM)	-57.53 %	-50.26 %	-53.07 %	-55.47 %	-65.68 %
RGLS's Total Ranking	# 3104	# 2590	# 2656	# 2385	# 2409
Equity (TTM) in Millions	69	76	87	98	108
Seq. Equity Change	-9.66 %	-11.98 %	-11.59 %	-8.74 %	407.8 %
Seq. Net Income Change	-	-	-	-	-

Back to RGLS Management Effectiveness >> RGLS's 5 Years Annual ROE >> Compare RGLS ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 182
Sector	# 440
Overall	# 3104

Return On Equity Statistics
High	Average	Low
-31.8 %	-4541.79 %	-163381.82 %
(June 30. 2014)		(Mar 31 2019)

RGLS Annual Return On Equity	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021	(Dec 31 2020) 2020
Total Equity in Millions	76	21	33	55	26
Y / Y Equity Change	260.64 %	-36.36 %	-39.42 %	111.17 %	30.03 %
Net Income in Millions	-46	-30	-28	-28	-16
Y / Y Net Income Change	-	-	-	-	-
Return On Equity	-60.67 %	-141.77 %	-85.08 %	-50.6 %	-60.44 %

Back to RGLS Management Effectiveness >> RGLS's 5 Years Annual ROE >> Compare RGLS ROE to its Competitors

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
RGLS's' Return on Equity at Yahoo Finance
RGLS's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for RGLS's Competitors
Subscribers only: Roe for Regulus Therapeutics Inc 's Suppliers
Subscribers only: Return On Equity for RGLS's Customers

Companies with similar Return On Equity at Mar 31 2025, within Healthcare Sector

ROE

Date modified: 2026-09-08T15:22:15+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.